Phase 3 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older
- People who are female
- People who have been diagnosed with breast cancer (either invasive or in situ) or a phyllodes tumour, confirmed by a tissue sample test
- People who have larger breasts (bra size 40 or above and/or D cup or larger) and have already had breast-conserving surgery (surgery that removes the tumour but keeps most of the breast)
- People who are scheduled to receive one of three types of radiation treatment to the whole or part of the breast, delivered while lying face-down
- People who are receiving radiation treatment with or without an additional targeted boost dose
- People who speak English, or who are able to participate with the help of a translator
Who may not be able to join:
- People who are planned to receive a type of internal radiation treatment (brachytherapy) in the treatment area, or who are scheduled to receive radiation to both breasts
- People who have previously had radiation treatment to any part of the area now being planned for treatment
- People who currently have a rash or an existing skin condition in the area planned for treatment
- People who are receiving certain chemotherapy medicines at the same time as radiation treatment
- People who are unable to lie face-down for radiation treatment
- People whose treatment plan involves placing a special material on the skin to adjust the radiation dose (called tissue equivalent bolus)
- People who have a known sensitivity or allergy to a medicine called betamethasone
- People who are known to be pregnant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Edward LW Chow, MBBS, Sunnybrook Health Sciences Centre
Phone: 416-480-4974
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Acute grade 2 or 3 toxicities as defined by the CTCAE v5.0 assessed by HCP
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.